High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma

This study is evaluating a combination of two radiation approaches — high dose-rate brachytherapy (radiation delivered from inside the body) and stereotactic body radiotherapy (precisely targeted external radiation) — for treating intermediate- to high-risk prostate cancer. **You may be eligible if...** - You are 18 or older - You have been diagnosed with intermediate- or high-risk prostate cancer confined to the prostate or nearby tissue (no lymph node or distant spread) - Your prostate is not too large (60cc or less) - Your urinary symptom score is acceptable (IPSS score 15 or below) - You are in generally good health (ECOG 0–2) - You are able to safely receive sedation or general anesthesia **You may NOT be eligible if...** - You have a rare type of prostate cancer (neuroendocrine or small cell) - You have had prior prostate surgery (prostatectomy), cryosurgery, or high-intensity focused ultrasound for prostate cancer - You have had pelvic radiation or prostate brachytherapy before - You have had another invasive cancer within the past 5 years - You have a history of inflammatory bowel disease - You had a prostate procedure (TURP) within the last 6 months - Cancer has spread to lymph nodes or distant sites Talk to your doctor to see if this trial is right for you.